The May 1, 2018, article by Juric et al entitled “Phosphatidylinositol 3-Kinase α -Selective Inhibition With Alpelisib (BYL719) in *PIK3CA*-Altered Solid Tumors: Results From the First-in-Human Study” (J Clin Oncol 36:1291-1299, 2018) was published online February 5, 2018, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

José Baselga

Leadership: Infinity Pharmaceuticals, Varian Medical Systems

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems, Northern Biologics, Tango Therapeutics, Foghorn Therapeutics

Consulting or Advisory Role: Eli Lilly, Novartis

Patents, Royalties, Other Intellectual Property: Memorial Sloan Kettering Cancer Center

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals, Varian Medical Systems, **GRAIL**

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems, Northern Biologics, Tango Therapeutics, Foghorn Therapeutics, **Aura Biomedical, Apogen**

Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, Northern Biologics

Consulting or Advisory Role: Eli Lilly, Novartis

Research Funding: Roche/Genentech

Patents, Royalties, Other Intellectual Property: **Combination therapy using PDK1 and PI3K inhibitors. Pending. Memorial Sloan Kettering (MSK) owned, listed as investigator. Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations. Licensed. MSK owned, listed as investigator. Inhibition of KMT2D for the treatment of breast cancer. Pending. MSK owned, listed as investigator.**

Travel, Accommodations, Expenses: Roche/Genentech, Daiichi, Bristol-Myers Squibb

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02208>

The May 1, 2018, article by Juric et al entitled “Phosphatidylinositol 3-Kinase α -Selective Inhibition With Alpelisib (BYL719) in *PIK3CA*-Altered Solid Tumors: Results From the First-in-Human Study” (J Clin Oncol 36:1291-1299, 2018) was published with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Burris’ COIs were given as:

Howard A. Burris

No relationship to disclose

They should have read as:

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: Mersana (Inst), AstraZeneca (Inst), FORMA Therapeutics (Inst), Janssen (Inst), Novartis (Inst), Roche/Genentech (Inst), TG Therapeutics (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst)

Research Funding: Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Tarveda Therapeutics (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), MacroGenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst), Moderna Therapeutics (Inst), CytomX Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), PTC Therapeutics (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), Valent Technologies (Inst), BioAtla (Inst), CicloMed (Inst), Harpoon Therapeutics (Inst), Jiangsu Hengrui Medicine (Inst), Revolution Medicines (Inst), Daiichi Sankyo (Inst), H3 Biomedicine (Inst), Neon Therapeutics (Inst), OncoMed (Inst), Regeneron (Inst), Sanofi (Inst)

Expert Testimony: Novartis

This has been corrected as of January 7, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02266>